Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a pioneering specialty pharmaceutical company dedicated to developing and commercializing next-generation, abuse-deterrent products aimed at treating chronic pain and other serious medical conditions. Leveraging its proprietary DETERx® technology platform, Collegium creates formulations designed to mitigate the risks associated with the misuse and abuse of prescription medications. The DETERx technology maintains the extended-release and safety profiles of commonly abused drugs, such as opioids and amphetamines, even when subjected to tampering methods like crushing, chewing, or dissolving.
Collegium's lead product, Xtampza ER™, is an extended-release, oral formulation of oxycodone that incorporates abuse-deterrent properties. The company's product portfolio also includes the Nucynta® Products (extended-release and immediate-release formulations of tapentadol), Belbuca® (buccal film for severe chronic pain), and Symproic® (for opioid-induced constipation).
In recent news, Collegium announced its financial results for the quarter ended September 30, 2023, reporting a solid financial performance and an optimistic outlook for 2025 and 2026. The company achieved record quarterly revenue for Belbuca and has initiated an Accelerated Share Repurchase (ASR) program, further demonstrating its commitment to returning value to shareholders. The extension of Nucynta's regulatory exclusivity through July 2026 has also strengthened the company's future market positioning.
Headquartered in Stoughton, Massachusetts, Collegium continues to focus on operational excellence and disciplined capital deployment to enhance shareholder value. The company remains committed to improving patient outcomes while addressing the growing challenges of prescription drug abuse.
For more details and the latest updates, visit Collegium Pharmaceutical's website.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its financial guidance for 2023, projecting net product revenues between $565 million and $580 million. Adjusted operating expenses are expected to range from $135 million to $145 million, while adjusted EBITDA is forecasted to be between $355 million and $370 million. Notably, the board has authorized a $100 million share repurchase program following a $19.1 million return to shareholders in 2022. The Federal Circuit upheld critical patents for Belbuca, ensuring market exclusivity until 2032.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the Federal Circuit upheld the validity of certain patents for Belbuca, blocking ANDA filer Alvogen from entering the market until 2032. The ruling confirms the strength of the company’s patents, including the '866 patent expiring in 2027 and the '539 patent set to expire in 2032. Alvogen conceded infringement on all claims, benefitting Collegium by ensuring Belbuca remains exclusively marketed until the patents expire.
Collegium Pharmaceutical (Nasdaq: COLL) announced participation in the Piper Sandler 34th Annual Healthcare Conference in New York from November 29 to December 1, 2022. Management will engage in a fireside chat on November 30, 2022, at 1:30 p.m. ET. The discussion will be webcast live and accessible via the Investors section of Collegium's website, with a replay available for 90 days post-event. Collegium is dedicated to enhancing the lives of individuals with serious medical conditions, headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical reported record net revenue of $127.0 million for Q3 2022, up from $78.8 million in Q3 2021. The company successfully renegotiated contracts for Xtampza® ER, achieving a gross-to-net less than 65% starting January 2023. Collegium returned $10 million to shareholders through repurchases. The updated full-year guidance estimates total product revenues between $455.0 and $465.0 million and adjusted EBITDA from $250.0 to $255.0 million. The company exited Q3 with $134.1 million in cash, highlighting strong operational performance.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is set to report its third quarter 2022 financial results on November 3, 2022, after market close. A live conference call will follow at 4:30 p.m. ET, accessible via telephone or webcast. Collegium continues to focus on its commitment to improving the lives of those with serious medical conditions, based in Stoughton, Massachusetts. For further details, listeners can access the webcast on the company’s website shortly after the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced 11 poster presentations at the Annual PAINWeek National Conference from September 6-9, 2022, in Las Vegas. These presentations showcase data on its differentiated products, particularly Xtampza® ER and Celecoxib Oral Solution. Dr. Thomas Smith highlighted the opportunity to share clinical insights, emphasizing the company's commitment to enhancing patient care for serious medical conditions. The research details the efficacy and safety of treatments while addressing risks like addiction and cardiovascular issues associated with their products.
Collegium Pharmaceutical reported record net revenue of $123.5 million for Q2 2022, a significant increase from $82.9 million in Q2 2021. Following the BDSI acquisition, the company completed phase one of its integration and is on track to exceed targeted synergies of at least $75 million. Full-year adjusted EBITDA guidance has been raised to between $245 million and $255 million. However, the company posted a net loss of $5.2 million, or $0.15 per share, compared to a net income of $72.8 million in the same quarter last year.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will announce its Q2 2022 financial results on August 4, 2022, after market closure. A corresponding conference call will be held at 4:30 p.m. ET, allowing investors to discuss the financial outcomes live. To participate, dial (877) 407-8037 for U.S. callers or (201) 689-8037 internationally, referencing the 'Collegium Pharmaceutical Q2 2022 Earnings Call.' An audio webcast will also be available on the company's website, with a replay accessible two hours post-event.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation at the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Collegium’s presentation is set for May 24, 2022, at 3:30 pm ET. The company is focused on improving the lives of those with serious medical conditions and is headquartered in Stoughton, Massachusetts. For more information, visit www.collegiumpharma.com.
Collegium Pharmaceuticals reported Q1 2022 net revenue of $83.8 million, down from $87.7 million in Q1 2021. The BDSI acquisition is on track to exceed targeted run rate synergies of $75 million. The company has resolved all opioid-related litigation and provided financial guidance for 2022, expecting revenues between $450 million and $465 million. Despite a net loss of $13.1 million this quarter, Collegium’s outlook remains positive with a cash balance of $106.7 million.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What is Collegium Pharmaceutical, Inc.?
What is DETERx® technology?
What are the main products offered by Collegium?
What recent financial achievements has Collegium reported?
Where is Collegium Pharmaceutical headquartered?
How does Collegium's DETERx® technology help in preventing drug abuse?
What is Xtampza ER™?
How does Collegium Pharmaceutical return value to its shareholders?
What is the significance of Nucynta's regulatory exclusivity extension?
How can I stay updated on Collegium Pharmaceutical's latest news?
